Inflammatory dermatoses are a broad family of skin conditions driven by immune system dysfunction rather than infection alone. They range from common problems like eczema and psoriasis to less familiar ones like hidradenitis suppurativa and granulomatous disorders, and they affect hundreds of millions of people worldwide. What unites them is that the skin’s own defense systems overreact or misfire, producing redness, swelling, scaling, blistering, or scarring. The underlying immune pathways vary substantially from one condition to another, and that variation increasingly guides how dermatologists choose treatments.
Why the Skin’s Defense System Turns on Itself
Healthy skin protects you through three overlapping layers of defense: a physical and chemical barrier (the outer skin itself), innate immunity (a fast, nonspecific response to invaders), and acquired immunity (a slower, targeted response that remembers specific threats). Inflammatory dermatoses arise when one or more of these layers malfunction. A barrier defect can let irritants in and moisture out. Innate immunity can become hyperactive, attacking the body’s own tissues. Acquired immunity can tip toward allergy or autoimmunity. One proposed classification framework groups inflammatory skin diseases according to which defensive layer has gone wrong, treating each condition as a misguided simulation of the response to a real infection or danger.1Journal of Dermatological Science. Classification of inflammatory skin diseases: A proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity
A more recent approach focuses on immunological signatures, grouping diseases by the specific immune response patterns they generate. These patterns include autoinflammation, cytotoxic responses, eczematous reactions, blistering responses, psoriasiform inflammation, and fibrosing or granulomatous processes.2PubMed Central. Inflammatory Skin Diseases: The Importance of Immunological Signatures The practical payoff of sorting conditions this way is that treatments can be matched to the dominant immune pathway rather than to the superficial appearance of the rash.
Psoriasis and the IL-23 Pathway
Psoriasis is one of the most studied inflammatory dermatoses, and its mechanism is now well mapped. The central driver is a signaling loop between immune cells called dendritic cells and a subset of T cells known as Th17 cells. Dendritic cells and skin cells overproduce a signaling molecule called IL-23, which stimulates Th17 cells to survive and multiply. Those Th17 cells, in turn, release IL-17A and IL-22. IL-22 in particular drives the rapid overgrowth of skin cells that produces the thick, scaly plaques characteristic of psoriasis.3PubMed Central. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines
IL-23 levels are measurably higher in psoriatic skin compared with unaffected skin on the same person, confirming its central role.4PubMed Central. The role of IL-23 and the IL-23/T(H) 17 immune axis in the pathogenesis and treatment of psoriasis Understanding this loop has been enormously productive for treatment design: several modern biologic drugs work by blocking IL-23 or IL-17 directly, effectively shutting down the inflammatory cascade at its source.
Atopic Dermatitis and the Broken Barrier
Atopic dermatitis (eczema) involves a different immune skew. Rather than the Th17-dominant inflammation seen in psoriasis, eczema is driven primarily by Th2 immune cells, which flood the skin with IL-4 and IL-13. These signaling molecules do more than cause itching and redness: they actively sabotage the skin barrier by reducing production of filaggrin, a protein essential for holding the outer skin layer together. Research has shown that keratinocytes exposed to IL-4 and IL-13 produce dramatically less filaggrin compared with untreated cells.5PubMed Central. Cytokine Modulation of AD Filaggrin Skin Expression
This creates a vicious cycle: immune activation weakens the barrier, a weakened barrier lets allergens and microbes penetrate more easily, and those invaders trigger further immune activation. As the disease becomes chronic, additional immune cell types (Th22 and Th17 cells) pile on, and their own signaling molecules suppress filaggrin even further.6Frontiers in Medicine. Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human Some people also carry genetic mutations that reduce filaggrin production independently, meaning they start with a compromised barrier before the immune system even gets involved.
Contact Dermatitis, Rosacea, and Hidradenitis Suppurativa
Not all inflammatory dermatoses fit neatly into the psoriasis or eczema model. Contact dermatitis, for instance, splits into two distinct types. Irritant contact dermatitis is a direct chemical injury to the skin, no immune memory required. Allergic contact dermatitis, by contrast, involves a learned immune response to a specific substance. The immune reaction varies by allergen: nickel, one of the most common culprits, triggers Th1, Th17, and Th22 responses, even though the visible rash looks the same regardless of which allergen caused it.7PubMed Central. IRRITANT AND ALLERGIC CONTACT DERMATITIS – SKIN LESION CHARACTERISTICS
Rosacea operates through yet another mechanism. The current understanding points to overactive innate immune pathways, particularly those involving cathelicidins (antimicrobial peptides the skin normally uses for defense) and inflammasome complexes, which are intracellular alarm systems that amplify inflammation.8PubMed Central. Rosacea: Pathogenesis and Therapeutic Correlates In rosacea, these alarm systems are tripped too easily by triggers like heat, UV light, spicy food, or alcohol, producing the characteristic flushing and papules.
Hidradenitis suppurativa (HS) takes a different path still. The disease begins with blockage (occlusion) of hair follicles, especially in skin folds like the armpits, groin, and under the breasts. Once a follicle is blocked, the trapped contents trigger an intense immune response.9Clinics in Dermatology. Hidradenitis suppurativa and follicular occlusion syndrome: Where is the pathogenetic link? HS involves both innate and adaptive immunity simultaneously: inflammasome-driven inflammation with heavy neutrophil involvement, plus strong Th1 and Th17 activation. Anaerobic bacteria and molecules released from damaged cells add fuel, creating self-sustaining cycles that produce painful abscesses, draining tunnels, and scarring.10British Journal of Dermatology. Aetiology and pathogenesis of hidradenitis suppurativa
How the Skin Microbiome Feeds Inflammation
Your skin is home to trillions of microorganisms, and the composition of that community matters enormously in inflammatory dermatoses. In atopic dermatitis, the bacterium Staphylococcus aureus tends to overgrow during flares, crowding out beneficial species and reducing overall microbial diversity. The severity of the overgrowth tracks with disease severity: worse colonization, worse eczema.11PubMed. Skin microbiome dysbiosis and the role of Staphylococcus aureus in atopic dermatitis in adults and children: A narrative review
This is not just a bystander effect. S. aureus actively damages the skin barrier and provokes inflammation through toxins called superantigens and through proteases that break down skin proteins. Certain strains produce virulence factors that can, on their own, trigger eczema-like symptoms in animal models.12PubMed Central. Skin Microbiome in Atopic Dermatitis The abnormal proliferation of S. aureus weakens the barrier further, increases susceptibility to allergens and irritants, and amplifies the immune response.13Frontiers in Medicine. Understanding the role of Staphylococcus aureus in atopic dermatitis: strain diversity, microevolution, and prophage influences Strategies aimed at restoring microbial balance, such as topical probiotics or targeted anti-staphylococcal approaches, are an active area of research.
Stress, Pollution, and Triggers That Aren’t Obvious
Chronic psychological stress is one of the most underappreciated drivers of inflammatory skin disease. A well-documented “brain-skin” connection links stress to flares of psoriasis, eczema, urticaria, and prurigo nodularis, and the relationship runs in both directions. Stress keeps the sympathetic nervous system in overdrive, which increases the density of nerve fibers and mast cells in the skin, elevates nerve growth factor, and promotes a particular neuropeptide called CGRP. CGRP pushes the immune response toward the Th2 pattern that characterizes eczema and chronic itch conditions.14PubMed. Cutaneous neuropeptides: the missing link between psychological stress and chronic inflammatory skin disease? The bidirectional nature means that having a visible, itchy skin disease increases stress, which in turn worsens the disease.
Air pollution is another external factor that compounds skin inflammation. Airborne particulate matter triggers oxidative stress in skin cells, provoking the release of inflammatory molecules like TNF-alpha and IL-8, and increasing enzymes that break down collagen.15Life Sciences. Air pollution and skin diseases: Adverse effects of airborne particulate matter on various skin diseases For people already prone to inflammatory dermatoses, pollution can act as a persistent, invisible trigger.
The gut may also play a role. A systematic review of the gut-skin axis found that reductions in beneficial gut bacteria like Bifidobacterium and Lactobacillus are linked to increased inflammatory signaling and weakened intestinal barrier function, potentially feeding systemic inflammation that manifests in the skin.16PubMed Central. The role of gut microbiome in inflammatory skin disorders: A systematic review This is still emerging science and should not be treated as an established treatment pathway, but it does help explain why some patients notice that dietary changes affect their skin.
Topical Treatments and the Steroid Question
Topical corticosteroids remain the first-line treatment for most inflammatory dermatoses. They work by broadly suppressing the local immune response and are available in a range of potencies, from mild hydrocortisone creams to very potent formulations for thick plaques. The main concern with long-term use is skin thinning (atrophy), especially on the face, eyelids, and skin folds where the skin is already thin.
Calcineurin inhibitors, including tacrolimus and pimecrolimus, offer a steroid-sparing alternative for these sensitive areas. A meta-analysis comparing the two drug classes for atopic dermatitis found similar overall effectiveness, but calcineurin inhibitors dramatically reduced the risk of skin atrophy compared with low-potency corticosteroids. The tradeoff is a higher rate of local burning or stinging sensation.17Ganesha Medicine. Comparative Efficacy and Safety of Topical Calcineurin Inhibitors Versus Low-Potency Corticosteroids in Atopic Dermatitis: A Systematic Review and Meta-Analysis Among the calcineurin inhibitors, tacrolimus appears to outperform pimecrolimus and may even beat weak corticosteroids in head-to-head comparisons, making it a particularly useful option for the face and intertriginous areas where steroid side effects are most worrisome.18PubMed. A Comparison of Topical Corticosteroids and Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis
Biologics and the Precision Medicine Shift
The biggest treatment revolution in inflammatory dermatology over the past decade has been biologics: engineered antibodies that block specific immune molecules. Rather than broadly suppressing the immune system, biologics zero in on individual targets within the inflammatory cascade.19PubMed Central. Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases
For atopic dermatitis, dupilumab was a landmark. It blocks the receptor shared by IL-4 and IL-13, the main drivers of Th2 inflammation. In clinical studies, dupilumab not only improved Th2-related markers but also reduced Th17 and Th22 signatures, suggesting it rebalances the immune environment more broadly than its target would imply.20PubMed Central. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
For psoriasis, the biologic menu is wider and increasingly tailored to the individual patient. Drugs targeting IL-17, IL-23, and the older IL-12/23 pathway are all available, and the choice among them may depend on factors like age, the location of plaques, and other health conditions the patient has.21PubMed. Tailored biological treatment for patients with moderate-to-severe psoriasis A personalized approach aims to maximize effectiveness while minimizing risk, because different biologics carry different side-effect profiles.
JAK Inhibitors and the Next Wave
Janus kinase (JAK) inhibitors represent a newer class of treatment that works differently from biologics. Where biologics are large protein molecules given by injection and act outside the cell, JAK inhibitors are small molecules that can be taken as pills or applied as creams. They work by blocking signaling pathways inside the cell that multiple inflammatory molecules rely on.22PubMed Central. Role of Janus Kinase Inhibitors in Therapy of Psoriasis
In atopic dermatitis, several oral JAK inhibitors (baricitinib, abrocitinib, upadacitinib) have met their primary goals across numerous clinical trials for moderate-to-severe disease. A topical JAK inhibitor, ruxolitinib cream, has also shown strong results for milder disease with minimal side effects.23PubMed Central. JAK inhibitors in the treatment of atopic dermatitis Beyond eczema and psoriasis, JAK inhibitors are being explored in a range of other inflammatory skin conditions including vitiligo, lichen planus, hidradenitis suppurativa, and dermatomyositis.24Indian Journal of Dermatology, Venereology and Leprology. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease
The main caution with oral JAK inhibitors is their broader immune effects. Because they block pathways used by multiple cytokines simultaneously, they carry risks that include increased susceptibility to infections and, in some patient populations, potential cardiovascular or malignancy concerns that have prompted regulatory warnings. Careful patient selection and monitoring are standard.
Phototherapy as a Drug-Free Option
Narrowband UVB (NB-UVB) phototherapy is one of the oldest targeted treatments still in regular use. It works by suppressing the skin’s cell-mediated immune response and is effective for a range of inflammatory dermatoses, particularly psoriasis, atopic dermatitis, and vitiligo.25PubMed Central. An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases
The mechanism involves several layers. UVB induces apoptosis (programmed death) of the overactive T cells in the skin.26PubMed Central. Narrow-Band UVB Phototherapy in the Treatment of Cutaneous Immune-Related Adverse Events From Immune Checkpoint Inhibitors: A Multicenter Retrospective Analysis At the same time, it shifts the local immune balance: treated patients produce more of the anti-inflammatory cytokine IL-10 while releasing markedly less of the pro-inflammatory molecules IL-1beta, IL-2, IL-5, and IL-6.27PubMed. Narrowband-UVB irradiation decreases the production of pro-inflammatory cytokines by stimulated T cells This combination of killing off inflammatory cells and rebalancing the remaining immune response helps explain why phototherapy can sometimes produce remissions that last well beyond the treatment period.
Phototherapy does require a commitment. Typical protocols involve two to three sessions per week in a clinical setting, which can be logistically difficult. Home units exist and are growing in availability, but the treatment still takes weeks to months to reach full effect. For patients who prefer to avoid systemic drugs or whose disease is not severe enough to justify biologics, it fills an important middle ground.
Inflammatory Skin Disease as a Systemic Problem
One of the most significant shifts in thinking about inflammatory dermatoses is the recognition that they are not purely skin-deep. Psoriasis is now considered a systemic inflammatory condition, with elevated blood markers of inflammation and evidence of inflammation in sites beyond the skin. The most clinically important consequence is cardiovascular disease: people with psoriasis face a measurably higher excess risk of heart attacks and strokes, and cardiovascular disease is the leading contributor to increased mortality in this population.28PubMed Central. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences
Atopic dermatitis and hidradenitis suppurativa also carry associations with metabolic syndrome, depression, and other systemic conditions, though the mechanisms are less fully mapped. The practical takeaway is that managing an inflammatory skin disease is not just about clearing the rash. It means paying attention to cardiovascular risk factors, mental health, and other organ systems that share the burden of chronic systemic inflammation.
Diagnosis in Darker Skin Tones
Most dermatology textbooks and training materials historically used images of lighter skin, which has real consequences for diagnosis. Inflammatory dermatoses can look quite different in darker skin. Redness, the classic hallmark of inflammation, may appear purple, brown, or dark gray instead of pink. Scaling may be more prominent, and the disease borders can be harder to distinguish.
Beyond missed or delayed diagnoses, darker-skinned patients face a particular complication: postinflammatory hyperpigmentation (PIH). This darkening of the skin at the site of previous inflammation is among the most common reasons people with darker skin seek dermatologic care, and it tends to be both more frequent and more severe in these populations.29PubMed Central. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color PIH can persist for months or even years after the underlying inflammation resolves, and for many patients it is more distressing than the original disease. Treating the inflammation aggressively and early is the single best way to prevent PIH, which underscores why delayed diagnosis has such outsized consequences for this group.
Non-Invasive Diagnostics and the Road to Precision
As treatments become more targeted, so does the need for accurate diagnosis and monitoring. A promising development is the use of tape stripping, a simple technique where adhesive strips are pressed against the skin to collect cells from the outermost layer. These strips can then be analyzed for inflammatory protein signatures. The method has been validated in atopic dermatitis, psoriasis, and hidradenitis suppurativa, and can distinguish between conditions, track treatment responses, and provide molecular insights without requiring a surgical biopsy.30PubMed. Tape strips in inflammatory skin disease: a noninvasive method for molecular insights and personalized care
In one cross-sectional study, targeted protein panels detected inflammatory biomarkers above measurable levels in about two-thirds of atopic dermatitis samples and roughly 70% of psoriasis samples, enough to reliably distinguish both conditions from healthy skin. Contact dermatitis was harder to differentiate using the same panel.31Acta Dermato-Venereologica. Assessing Targeted Proteomics in Inflammatory Skin Diseases with the Tape-stripping Method Tape strips have also been shown to capture changes in immune markers during treatment, tracking suppression of Th2 and Th17/Th22 markers in atopic dermatitis patients treated with topical corticosteroids, in agreement with what biopsies would show.32The Journal of Allergy and Clinical Immunology: In Practice. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity
When Inflammation Mimics Cancer
One reason accurate diagnosis matters so much is that certain malignancies can masquerade as benign inflammatory skin conditions. Mycosis fungoides, the most common form of cutaneous T-cell lymphoma, is a cancer of skin-homing helper T cells. Early-stage mycosis fungoides can look remarkably like eczema or psoriasis, with flat, scaly patches that respond partially to topical steroids, further blurring the diagnostic line.33Journal of the American Academy of Dermatology. Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: Diagnostic implications Dermatologists often need repeated biopsies and immunohistochemical staining to tell the two apart. For patients who have persistent, treatment-resistant patches of what looks like eczema or psoriasis, especially in unusual distributions, this diagnostic possibility is worth raising with a dermatologist. Catching lymphoma early dramatically affects outcomes, and the clinical overlap with common inflammatory dermatoses is one of the main reasons it gets caught late.